Delving into the Latest Updates on Trastuzumab biosimilar(Tanvex Biopharma, Inc.) with Synapse

Overview

Basic Info

Drug Type

Biosimilar, Monoclonal antibody

Synonyms

Trastuzumab biosimilar

Target

HER2

Mechanism

HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Breast Cancer 3Early Stage Breast CarcinomaHER2 Positive Breast Cancer

Originator Organization

Tanvex BioPharma, Inc.

Active Organization-

Inactive Organization

Tanvex BioPharma USA, Inc.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 18481L

The sequence is quoted from: *****

Sequence Code 44772H

The sequence is quoted from: *****

The aggregation structure of Triton X (TX) amphiphilic mols. in aqueous solution plays an important role in determining the various properties and applications of surfactant solutionsIn this paper, the properties of micelles formed by TX-5, TX-114, and TX-100 mols. with different poly(ethylene oxide) (PEO) chain lengths in TX series of nonionic surfactants were studied via mol. dynamics (MD) simulation.The structural characteristics of three micelles were analyzed at the mol. level, including the shape and size of micelles, the solvent accessible surface area, the radial distribution function, the micelle configuration, and the hydration numbersWith the increase of PEO chain length, the micelle size and solvent accessible surface area also increase.The distribution probability of the polar head oxygen atoms on the surface of the TX-100 micelle is higher than that in the TX-5 or TX-114 micelle.In particular, the tail quaternary carbon atoms in the hydrophobic region are mainly located at the micelle exterior.For TX-5, TX-114, and TX-100 micelles, the interactions between micelles and water mols. are also quite different.These structures and comparisons at the mol. level contribute to the further understanding of the aggregation and applications of TX series surfactants.

100 Deals associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC03	DB00072

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Breast Cancer	Phase 3	BY	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	MX	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	PE	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	IN	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	GE	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	UA	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	CL	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	RU	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	PH	Tanvex BioPharma USA, Inc.	28 Jun 2018
HER2 Positive Breast Cancer	Phase 3	HU	Tanvex BioPharma USA, Inc.	28 Jun 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04109391 (TX05-03e \| TX05-03, CTgov)	Phase 3	HER2 Positive Breast Cancer \| Early Stage Breast Carcinoma \| Breast Cancer 3	338	TX05 (trastuzumab)	zsiywebajd(pwlrvfvzjv) = ccuoarpmvl gqyagnsqux (povkxyosoq, rmxrdxjsbi - vygyszuvll) View more	-	26 Oct 2022
NCT04109391 (TX05-03, ASCO2022) Manual	Phase 3	HER2 Positive Breast Cancer Neoadjuvant HER2 Positive	338	TX05	(gaqwcsikji) = eksswrogay wtiddozcrd (kdzfhzidrv ) View more	Positive	08 Jun 2022
				trastuzumab+TX05	(gaqwcsikji) = kzogautvkg wtiddozcrd (kdzfhzidrv ) View more
NCT03556358 (CTgov)	Phase 3	HER2 Positive Breast Cancer \| Breast Cancer 3	809	CYCLOPHOSPHAMIDE+Paclitaxel+Epirubicin+TX05 (trastuzumab) (TX05 (Trastuzumab))	avcnxrajuv(upfiuvbuip) = plhvynatcs nzwfdoelpv (fxauodnwhq, ymrkrvdixa - uzhsplvbod) View more	-	14 Jan 2022
				Herceptin®+CYCLOPHOSPHAMIDE+Paclitaxel+Epirubicin (Herceptin®)	avcnxrajuv(upfiuvbuip) = mnuqfjzaqj nzwfdoelpv (fxauodnwhq, jggajsgqid - cytdxpthqd) View more
EUCTR2017-004190-13-BG \| NCT03556358 (TX05-03, ESMO 12021 \| ESMO 22021) Manual	Phase 3	HER2 Positive Breast Cancer HER2 Positive	809	epirubicin+cyclophosphamide+paclitaxel+TX05	(sxspmnzzfp) = lyqhrqymkk bpetpfyxmv (jtyikinvyr ) View more	Similar	16 Sep 2021
				epirubicin+cyclophosphamide+paclitaxel+trastuzumab (TRA)	(sxspmnzzfp) = zswpzzlzdy bpetpfyxmv (jtyikinvyr ) View more